Evolution of antiemetic studies for radiation-induced nausea and vomiting within an outpatient palliative radiotherapy clinic

[1]  Hans T. Chung,et al.  Management of radiation-induced nausea and vomiting with palonosetron in patients with pre-existing emesis: a pilot study. , 2018, Annals of palliative medicine.

[2]  Hans T. Chung,et al.  A pilot study with palonosetron in the prophylaxis of radiation-induced nausea and vomiting. , 2018, Annals of palliative medicine.

[3]  M. Kris,et al.  Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  T. Ashikaga,et al.  Effectiveness of aprepitant in addition to ondansetron in the prevention of nausea and vomiting caused by fractionated radiotherapy to the upper abdomen (AVERT) , 2017, Supportive Care in Cancer.

[5]  A. Matsumura,et al.  Combination of Palonosetron, Aprepitant, and Dexamethasone Effectively Controls Chemotherapy-induced Nausea and Vomiting in Patients Treated with Concomitant Temozolomide and Radiotherapy: Results of a Prospective Study , 2016, Neurologia medico-chirurgica.

[6]  C. Vidall,et al.  Patient-practitioner perception gap in treatment-induced nausea and vomiting. , 2016, British journal of nursing.

[7]  E. Bruera,et al.  2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  H. Friedman,et al.  Phase II study to evaluate the safety and efficacy of intravenous palonosetron (PAL) in primary malignant glioma (MG) patients receiving standard radiotherapy (RT) and concomitant temozolomide (TMZ) , 2016, Supportive Care in Cancer.

[9]  G. Kristensen,et al.  Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial. , 2016, The Lancet. Oncology.

[10]  D. Vordermark,et al.  Addition of the Neurokinin-1-Receptor Antagonist (RA) Aprepitant to a 5-Hydroxytryptamine-RA and Dexamethasone in the Prophylaxis of Nausea and Vomiting Due to Radiation Therapy With Concomitant Cisplatin. , 2015, International journal of radiation oncology, biology, physics.

[11]  A. Feizi,et al.  The efficacy of combination of ondansetron and aprepitant on preventing the radiotherapy-induced nausea and vomiting , 2015, Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences.

[12]  C DeAngelis,et al.  Ondansetron rapidly dissolving film for the prophylactic treatment of radiation-induced nausea and vomiting-a pilot study. , 2015, Current oncology.

[13]  E. Chow,et al.  Efficacy of granisetron and aprepitant in a patient who failed ondansetron in the prophylaxis of radiation induced nausea and vomiting: a case report. , 2015, Annals of palliative medicine.

[14]  A. Sahgal,et al.  Aprepitant and granisetron for the prophylaxis of radiotherapy-induced nausea and vomiting after moderately emetogenic radiotherapy for bone metastases: a prospective pilot study. , 2014, Current oncology.

[15]  Liying Zhang,et al.  Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials , 2014, Supportive Care in Cancer.

[16]  Stephen Szabo,et al.  Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE Study. , 2014, Journal of oncology practice.

[17]  J. Herrstedt,et al.  Palonosetron and prednisolone for the prevention of nausea and emesis during fractionated radiotherapy and 5 cycles of concomitant weekly cisplatin—a phase II study , 2013, Supportive Care in Cancer.

[18]  Liying Zhang,et al.  International patterns of practice in the management of radiation therapy-induced nausea and vomiting. , 2012, International journal of radiation oncology, biology, physics.

[19]  A. Sahgal,et al.  Prophylaxis of radiotherapy-induced nausea and vomiting in the palliative treatment of bone metastases , 2012, Supportive Care in Cancer.

[20]  M. Kris,et al.  Antiemetics: American Society of Clinical Oncology clinical practice guideline update. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  R. Orecchia,et al.  A prospective observational trial on emesis in radiotherapy: analysis of 1020 patients recruited in 45 Italian radiation oncology centres. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[22]  K. Ding,et al.  5-hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: a placebo-controlled randomized trial of the National Cancer Institute of Canada Clinical Trials Group (SC19). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  P. Nathan,et al.  Options for the Prevention and Management of Acute Chemotherapy-Induced Nausea and Vomiting in Children , 2003, Paediatric drugs.

[24]  H. Åhlman,et al.  © 2001 Kluwer Academic Publishers. Printed in the Netherlands. Review The gut as the largest endocrine organ in the body , 2022 .

[25]  J. Raschko,et al.  Double-blind, randomized, parallel-group study on the efficacy and safety of oral granisetron and oral ondansetron in the prophylaxis of nausea and vomiting in patients receiving hyperfractionated total body irradiation , 2000, Bone Marrow Transplantation.

[26]  E. Perez,et al.  ASHP Therapeutic Guidelines on the Pharmacologic Management of Nausea and Vomiting in Adult and Pediatric Patients Receiving Chemotherapy or Radiation Therapy or Undergoing Surgery. , 1999, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[27]  R. Naylor,et al.  Neuropharmacology of emesis and its relevance to anti-emetic therapy , 1998, Supportive Care in Cancer.

[28]  P. Feyer,et al.  Aetiology and prevention of emesis induced by radiotherapy , 1998, Supportive Care in Cancer.

[29]  S. Fosså,et al.  Prophylactic use of tropisetron or metoclopramide during adjuvant abdominal radiotherapy of seminoma stage I: a randomised, open trial in 23 patients. , 1997, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[30]  M. Grant,et al.  Physiologic mechanisms of nausea and vomiting in patients with cancer. , 1997, Oncology nursing forum.

[31]  R. Naylor,et al.  Mechanisms of chemotherapy/radiotherapy-induced emesis in animal models. , 1996, Oncology.

[32]  Priestman Tj.  Controlling the toxicity of palliative radiotherapy: the role of 5-HT3 antagonists. , 1996 .

[33]  H. Prentice,et al.  Granisetron in the prevention of irradiation-induced emesis. , 1995, Bone marrow transplantation.

[34]  U. Verma,et al.  Interleukin-2 activation of chemotherapy and growth factor-mobilized peripheral blood stem cells for generation of cytotoxic effectors. , 1995, Bone marrow transplantation.

[35]  R. Henriksson,et al.  The effect of ondansetron on radiation-induced emesis and diarrhoea. , 1992, Acta oncologica.

[36]  H. L. Borison,et al.  Physiology and pharmacology of vomiting. , 1953, Pharmacological reviews.